A61K 2239/39
Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by a
Official title: characterised by a specific adjuvant, e.g. cytokines or CpG
A61K2239/39 (Indexing codes associated with cellular immunotherapy of group a61k40/00: characterised by a) appears on 10 US grants and 118 published applications in this corpus.
Search patents in A61K- Granted patents
- 10
- Published applications
- 118
- Assignees
- 85
- Inventors
- 331
- Latest grant
- 14 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 2 |
| 2010 | 0 | 0 |
| 2011 | 1 | 1 |
| 2012 | 1 | 1 |
| 2013 | 0 | 13 |
| 2014 | 1 | 0 |
| 2015 | 2 | 1 |
| 2016 | 0 | 0 |
| 2017 | 0 | 2 |
| 2018 | 0 | 0 |
| 2019 | 0 | 0 |
| 2020 | 0 | 2 |
| 2021 | 1 | 3 |
| 2022 | 1 | 4 |
| 2023 | 0 | 10 |
| 2024 | 0 | 29 |
| 2025 | 0 | 29 |
| 2026 | 3 | 21 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Treatment with tumor infiltrating lymphocyte therapies in combination with CTLA-4 and PD-1 inhibitors14 Jul 2026US 12,678,499 B2Iovance Biotherapeutics, Inc.
- Methods for treating HPV-associated diseases14 Apr 2026US 12,599,656 B2
- Immune-enhancing RNAs for combination with chimeric antigen receptor therapy3 Feb 2026US 12,539,308 B2Novartis AG
- Cell surface coupling of nanoparticles1 Mar 2022US 11,261,226 B2Massachusetts Institute of Technology (Mitn1)
- Cell surface coupling of nanoparticles15 Jun 2021US 11,034,752 B2Massachusetts Institute of Technology
- Anti-pd-1 chimeric antigen receptor t cells and therapeutic uses thereof20 Aug 2026US 2026/0240908 A1Fred Hutchinson Cancer Center
- Therapeutic targeting of tumor escape by car-mediated trogocytosis20 Aug 2026US 2026/0241002 A1University of Maryland, Baltimore
- Function-enhanced cell therapy13 Aug 2026US 2026/0232731 A1Nanjing Bioheng Biotech Co., Ltd.
- Immune-enhancing rnas for combination with chimeric antigen receptor therapy30 Jul 2026US 2026/0216224 A1Novartis AG
- Chimeric antigen receptor constructs with optimized intracellular domains for natural killer cells30 Jul 2026US 2026/0216246 A1
Most cited
By later US patents
- Oncolytic herpes simplex virus immunotherapy in the treatment of brain cancer7US 8,313,896 B2The General Hospital Corporation · 2012
- Cell surface coupling of nanoparticles4US 11,034,752 B2Massachusetts Institute of Technology · 2021
- Dendritic cell tumor injection (DCTI) therapy2US 9,089,593 B2Hasumi International Research Foundation · 2015
- Cell surface coupling of nanoparticles1US 11,261,226 B2Massachusetts Institute of Technology (Mitn1) · 2022
- Lipid membrane structure having intranuclear migrating property1US 8,981,044 B2National University Corporation Hokkaido University · 2015